Dianthus Therapeutics (NASDAQ:DNTH) is accelerating the development of its lead immunology candidate after an interim analysis of its Phase 3 CAPTIVATE trial yielded positive results earlier than anticipated.
The company reached a formal "GO" decision for the trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) after recording 20 confirmed responders.
Notably, the milestone was achieved with fewer than 40 participants completing the open-label Part A portion of the study, suggesting a robust early response rate for its C1s-targeted therapy.
Financially, Dianthus remains on firm footing to support its expanding pipeline.
The company reported $514.4 million in cash and equivalents as of December 31, 2025, a balance it expects will fund operations into 2028.
For the full year 2025, research and development expenses totaled $145.6 million, contributing to a net loss of $162.3 million as the firm scaled up its late-stage clinical infrastructure.
Beyond CIDP, Dianthus is preparing for a heavy slate of catalysts through 2026.
A Phase 3 trial in generalized Myasthenia Gravis (gMG) is slated to begin by mid-2026, with top-line results targeted for the second half of 2028.
Investors are also looking toward the second half of 2026 for top-line Phase 2 data in Multifocal Motor Neuropathy (MMN) and initial Phase 1 healthy volunteer data for DNTH212, its next-generation bifunctional inhibitor.